title: Changes in serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunoglobulin therapy.
abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a slowly progressive or recurrent neuropathy accompanied by infiltration of macrophages in the peripheral nerves. Macrophage colony-stimulating factor (M-CSF) and monocyte chemoattractant protein-1 (MCP-1) are a macrophage-related cytokine and chemokine, respectively. Although, intravenous immunoglobulin (IVIg) infusion therapy has been used for treating CIDP patients, not all CIDP patients have responded to IVIg infusion therapy. To determine the mechanisms of the action of IVIg, we examined serum M-CSF and MCP-1 levels during and after IVIg infusion therapy in 19 CIDP patients treated with IVIg (0.4 g/kg/day for 5 days). Ten of the 19 patients (52.6%) responded to IVIg therapy. Both M-CSF and MCP-1 concentrations in IVIg responders were significantly higher on day 1 postinfusion than those in nonresponders, but decreased to their pretreatment values on day 5 postinfusion. The results suggest that immunomodulation through M-CSF and MCP-1 is involved in the mechanisms underlying the effect of IVIg infusion therapy in CIDP patients.
authors.affiliation: Department of Clinical Neuroscience and Therapeutics, Division of Integrated Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Japan. kazuhide@hiroshima-u.ac.jp
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Ochi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kohriyama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Higaki
authors.forename: Junko
authors.initials: J
authors.lastname: Ikeda
authors.forename: Akira
authors.initials: A
authors.lastname: Harada
authors.forename: Shigenobu
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000097:blood*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D008262:Macrophage Activation; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood*; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000097:blood* / Q000628:therapy; D013997:Time Factors
chemical_list: D018932:Chemokine CCL2; D016756:Immunoglobulins, Intravenous; D016173:Macrophage Colony-Stimulating Factor